Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19

Phase 1

Completed

Conditions: Healthy
Chronic Stable Illness

Interventions: Drug: REGN10933+REGN10987
Drug: Placebo

First Posted Date: 2020-08-19

Last Posted Date: 2022-01-26

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 974

Registration Number: NCT04519437

Locations: 🇺🇸
Regeneron Study Site, Austin, Texas, United States

Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)

Active, not recruiting

Conditions: Retinopathy of Prematurity

Interventions: Other: Non-Interventional

First Posted Date: 2020-08-17

Last Posted Date: 2025-05-14

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT04515524

Locations: 🇹🇭
Queen Sirikit National Institute Of Child Health - Pediatrics, Bangkok, Thailand
🇺🇸
UCSD Shiley Eye Institute, Jacobs Retina Center, La Jolla, California, United States
🇺🇸
Loma Linda University Eye Institute, Loma Linda, California, United States

and more 27 locations

Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: REGN5381
Other: Placebo

First Posted Date: 2020-08-10

Last Posted Date: 2022-12-20

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 90

Registration Number: NCT04506645

Locations: 🇧🇪
Universitair Ziekenhuis Leuven Gasthuisberg Campus, Leuven, Belgium
🇧🇪
Ghent University, Ghent, Belgium

Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Pozelimab

First Posted Date: 2020-07-29

Last Posted Date: 2021-03-23

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT04491838

Locations: 🇧🇪
Regeneron Study Site, Antwerpen, Belgium

Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies

Phase 1

Terminated

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: REGN6569
Drug: Cemiplimab

First Posted Date: 2020-07-10

Last Posted Date: 2025-02-24

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 38

Registration Number: NCT04465487

Locations: 🇺🇸
Angeles Clinic and Research Institute - Clinic/Outpatient Facility, Los Angeles, California, United States
🇺🇸
H.Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

and more 7 locations

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

Phase 3

Completed

Conditions: Healthy Participants

Interventions: Drug: REGN10933 + REGN10987
Drug: Placebo

First Posted Date: 2020-06-30

Last Posted Date: 2023-05-15

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 3303

Registration Number: NCT04452318

Locations: 🇷🇴
Regeneron Study Site, Bucharest, Romania
🇺🇸
Regeneron Study Site 2, Bronx, New York, United States
🇺🇸
Regeneron Study Site 3, Chicago, Illinois, United States

and more 1 locations

Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)

Phase 2

Completed

Conditions: Allergic Bronchopulmonary Aspergillosis

Interventions: Drug: Placebo
Drug: dupilumab

First Posted Date: 2020-06-22

Last Posted Date: 2025-04-04

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT04442269

Locations: 🇬🇧
Regeneron Study Site, Bradford, West Yorkshire, United Kingdom

Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease

Phase 2

Completed

Conditions: Type 1 Diabetes Mellitus
Diabetic Macular Edema
Type 2 Diabetes Mellitus

Interventions: Drug: High-dose aflibercept
Drug: aflibercept

First Posted Date: 2020-06-12

Last Posted Date: 2024-07-30

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 660

Registration Number: NCT04429503

Locations: 🇭🇺
Regeneron Study Site 1, Pecs, Baranya, Hungary
🇬🇧
Regeneron Study Site, London, United Kingdom
🇺🇸
Regeneron Study Site 2, San Antonio, Texas, United States

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19

Phase 1

Completed

Conditions: COVID-19

Interventions: Drug: REGN10933+REGN10987 combination therapy
Drug: Placebo

First Posted Date: 2020-06-11

Last Posted Date: 2023-01-27

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 2252

Registration Number: NCT04426695

Locations: 🇷🇴
Regeneron Study Site, Bucuresti, Romania
🇲🇽
Regeneron Study Site 1, Mérida, Mexico
🇲🇽
Regeneron Study Site 2, Mérida, Mexico

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19

Phase 3

Terminated

Conditions: COVID-19

Interventions: Drug: casirivimab+imdevimab combination therapy

First Posted Date: 2020-06-11

Last Posted Date: 2023-12-21

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 10078

Registration Number: NCT04425629

Locations: 🇷🇴
Regeneron Study Site, Bucuresti, Romania
🇺🇸
Regeneron Study Site 1, Downers Grove, Illinois, United States
🇺🇸
Regeneron Study Site 3, Long Beach, California, United States

and more 1 locations

Home Terms & Conditions Privacy Policy